Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN®) in Patients with Diabetic Macular Edema

Ophthalmology and Therapy

Volumn 5, Issue 1, 2016, Pages 95-104

  Elaraoud, Ibrahim ^a   Attawan, Alaa ^b   Quhill, Fahd ^b  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bilateral diabetic macular edema; Central retinal thickness; Fluocinolone acetonide; Optical coherence tomography; Visual acuity

Indexed keywords

BIMATOPROST; BRINZOLAMIDE PLUS TIMOLOL; FLUOCINOLONE ACETONIDE; LATANOPROST PLUS TIMOLOL; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; COMPARATIVE STUDY; DEMOGRAPHY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VERY ELDERLY; VISUAL ACUITY; VITRECTOMY;

EID: 85015586912     PISSN: 21938245     EISSN: 21936528     Source Type: Journal    
DOI: 10.1007/s40123-016-0045-7     Document Type: Article

References (22)

1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.
2. Minassian D, Owens D, Reidy A, et al. (2008) Diabetic macular oedema and related sight loss at first screening for eye disease. The Wales Diabetic Retinopathy Screening Service (WDRSS). UK Vision Strategy 2010.
3. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7–16.
4. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626–35.
5. Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28(Suppl):452–61.
6. Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4:151–69.
7. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.
8. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
9. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–22.
10. Dong N, Xu B, Wang B, et al. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19:1734–46.
11. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152:686–94.
12. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38:218–45.
13. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–58.
14. European Medicines Agency. ILUVIEN 190 micrograms intravitreal implant in applicator: summary of products characteristics [online]. Available from: https://www.medicines.org.uk/emc/medicine/27636. Accessed June 26, 2015.
15. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117:1393–9.
16. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–32.
17. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30:1046–50.
18. Bron AM, Viswanathan AC, Thelen U, et al. International vision requirements for driver licensing and disability pensions: using a milestone approach in characterization of progressive eye disease. Clin Ophthalmol. 2010;4:1361–9.
19. Data on File, 2015. Alimera Sciences Ltd.
20. Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014;10:CD007419.
21. Downey L, Chakravarthy U. Exploratory analyses of long-term visual outcomes based on baseline vision in patients with chronic and nonchronic diabetic macular oedema (DMO) treated with fluocinolone acetonide (FAc) [abstract no.221]. Royal College of Ophthalmologists Annual Congress 19–21 May 2015.
22. Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (An AOS thesis). Trans Am Ophthalmol Soc. 2009;107:311–24.